Results 211 to 220 of about 851,166 (333)

High Radiation Resistance in the Binary W‐Ta System Through Small V Additions: A New Paradigm for Nuclear Fusion Materials

open access: yesAdvanced Science, EarlyView.
Refractory high‐entropy alloys exhibit superior radiation tolerance, but face fabrication challenges due to complex compositions. It is demonstrated that reducing the number of alloying elements does not compromise radiation resistance in a novel W‐Ta‐V highly‐concentrated refractory alloy.
Matheus A. Tunes   +16 more
wiley   +1 more source

The relationship between chlorophyllous spores and mycorrhizal associations in ferns: evidence from an evolutionary approach

open access: yesAmerican Journal of Botany, Volume 109, Issue 12, Page 2068-2081, December 2022., 2022
Abstract Premise Approximately 14% of all fern species have physiologically active chlorophyllous spores that are much more short‐lived than the more common and dormant achlorophyllous spores. Most chlorophyllous‐spored species (70%) are epiphytes and account for almost 37% of all epiphytic ferns.
Daniela Mellado‐Mansilla   +6 more
wiley   +1 more source

DiffMC‐Gen: A Dual Denoising Diffusion Model for Multi‐Conditional Molecular Generation

open access: yesAdvanced Science, EarlyView.
DiffMC‐Gen, a dual‐diffusion model for 2D and 3D molecular generation, simultaneously optimizes multiple key objectives across the drug design process, enabling the generation of novel, target‐specific small‐molecule ligands with high therapeutic potential.
Yuwei Yang   +7 more
wiley   +1 more source

Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia

open access: yesAmerican Journal of Hematology, Volume 98, Issue 1, Page 122-130, January 2023., 2023
Abstract Major options for second‐line therapy in adults with chronic immune thrombocytopenia (ITP) include splenectomy, rituximab, and thrombopoietin receptor agonists (TRAs). The American Society of Hematology guidelines recommend rituximab over splenectomy, TRAs over rituximab, and splenectomy or TRAs while noting a lack of evidence on the cost ...
George Goshua   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy